NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL MEASURES THAN SUCH MEASURES STIPULATED BY SWEDISH LAW.

The subscription price for warrants of series TO1A issued as part of the rights issue in aXichem AB (publ) ("aXichem" or the "Company") which was completed in April 2024 has been set to SEK 0.95. The subscription price corresponds to 70 percent of the volume-weighted average price of the Company's shares on Nasdaq First North Growth Market during the period October 1 – October 7, 2024.

The warrants can be exercised during the period 8 October – 21 October 2024 to subscribe for newly issued shares in aXichem for SEK 0.95 per share. Holders of warrants who do not wish to exercise them can sell the warrants on Nasdaq First North Growth Market until October 17, 2024. Warrants that are not sold or exercised will expire without value after 21 October 2024. Please note that some trustees may close their exercise period earlier than 21 October 2024.

Terms summary for warrants of series TO1A

Exercise period: 8 October – 21 October 2024.

Size: 18,809,290 warrants of series TO1A entitle holders to subscribe for 18,809,290 shares of class A in the Company. If all warrants are exercised, the Company will receive issue proceeds of approximately SEK 17.9 million before issue costs.

Subscription price: SEK 0.95 per share.

Last day for trading in warrants of series TO1A: October 17, 2024.

Complete terms and conditions for the warrants are available on the Company's website www.axichem.com.

Advisers
Västra Hamnen Corporate Finance AB is financial advisor and Advokatfirman Vinge is legal advisor to aXichem in connection with the Rights Issue. Nordic Issuing acts as issuing agent.

For more information:
Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: torsten.helsing@axichem.com
 

Certified adviser for aXichem is Västra Hamnen Corporate Finance AB.

The information was submitted, through the agency of the above contact person, for publication on October 7, 2024, at 20:30 CEST.

About aXichem

aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey, as an ingredient in food supplements for gut health, weight control and sports and exercise, and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. More information is available at www.axichem.com.